Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib Long-Term Safety in CML and Ph+ ALL
NCT00982488Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2007
- Primary completion
- Dec 2014
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 24
01
Overview
Phase 2, open-label trial of dasatinib in chronic myeloid leukemia (CML) and Acute lymphoblastic leukemia, Philadelphia chromosome positive (5 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Number of Participants Who Died and Had Serious Adverse Events (SAEs), Related SAEs, Adverse Events (AEs) Leading to Discontinuation, Related AEs Leading to Discontinuation, Related AEs, and Related… at 82 months. Started Oct 2007; status: completed.
02
Drugs
dasatinib
03
Conditions
chronic myeloid leukemia (CML)Acute lymphoblastic leukemia, Philadelphia chromosome positive
Beyond the preview
Go deeper on NCT00982488.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00982488.